Ruffer Investment Company apologises for sharp drop in the defensive global trust's assets last year, a fall that damages its reputation for capital preservation.
The £2.5 billion Dundee-based global fund is cutting the fees it pays senior non-executive directors as it puts finishes four-year retrenchment programme.
Citywire AA-rated Nick Train has used a dip in the price of Celtic following the exit of coach Brendan Rodgers to top up his position in the business.
Rothschild's RIT Capital Partners succeeded in protecting shareholders from last year's losses but Brexit deadlock and other geopolitical tensions keep veteran investor cautious about year ahead.
It's early days for Terry Smith's five-month-old global mid-cap trust but the £991 million listed fund has already had its share of ups and downs.
UK’s largest listed life sciences fund benefits from its first takeover after Nightstar Thereapeutics, its third biggest investment, falls to a knockout $877 million (£663 million) cash bid from Biogen of Switzerland.
Rising energy prices help high-yielding wind and solar power investment companies wean themselves off government subsidy and make the sector more resilient.
Beleaguered star fund manager Neil Woodford reorganises ownership of his unquoted investments in move that will see his flagship Equity Income fund become second largest shareholder in his Patient Capital investment trust.
Financial Conduct Authority agrees to address flaws in key information documents after admitting their figures on performance and costs can mislead investors.
‘Until and unless there are substantive and substantiated charges we remain confident that the company is strong and well placed to prosper,’ says star fund manager of Jupiter European Opportunities.